Theriva Biologics reported Q1 2026 financial results with $14.4 million cash, aligning with FDA on VCN-01 Phase 3 trial design for metastatic PDAC and advancing retinoblastoma program.
Key takeaways
FDA aligned on Phase 3 trial design for VCN-01 with gemcitabine/nab-paclitaxel in metastatic PDAC, including repeated dosing macrocycles.
Cash and cash equivalents of $14.4 million as of March 31, 2026, providing runway into Q1 2027.
G&A expenses increased 43% to $2.1 million due to higher legal fees, investor relations, and salaries.
R&D expenses decreased 88% to $355,000 following VIRAGE Phase 2b trial completion.
VCN-01 compassionate use in two retinoblastoma patients to support potential Phase 2/3 trial starting December 2026.
Additional VIRAGE data at AACR showed immune-mediated action and improved OS/PFS in VCN-01 subgroups.